FY2026 EPS Estimates for MMSI Raised by Barrington Research

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Barrington Research raised their FY2026 earnings per share estimates for shares of Merit Medical Systems in a note issued to investors on Monday, December 23rd. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will earn $4.28 per share for the year, up from their previous estimate of $4.25. Barrington Research has a “Outperform” rating and a $114.00 price target on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share.

Merit Medical Systems (NASDAQ:MMSI) last posted its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The company had revenue of $339.85 million during the quarter, compared to analysts’ expectations of $334.60 million. Merit Medical Systems’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.75 earnings per share.

Several other brokerages have also issued reports on MMSI. Wells Fargo & Company upgraded shares of Merit Medical Systems from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $103.00 to $120.00 in a research report on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Merit Medical Systems in a report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and set a $109.00 price objective on shares of Merit Medical Systems in a research note on Thursday, October 31st. Canaccord Genuity Group raised their target price on Merit Medical Systems from $125.00 to $127.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Bank of America boosted their price target on Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a research report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $105.60.

Merit Medical Systems Stock Performance

NASDAQ MMSI opened at $98.08 on Wednesday. The firm has a market capitalization of $5.72 billion, a P/E ratio of 48.08, a PEG ratio of 2.55 and a beta of 0.84. The stock has a 50-day simple moving average of $100.84 and a two-hundred day simple moving average of $94.15. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. Merit Medical Systems has a fifty-two week low of $70.70 and a fifty-two week high of $108.07.

Institutional Trading of Merit Medical Systems

A number of institutional investors and hedge funds have recently made changes to their positions in MMSI. USA Financial Formulas bought a new position in shares of Merit Medical Systems during the third quarter worth about $59,000. National Bank of Canada FI bought a new position in Merit Medical Systems in the 2nd quarter worth about $77,000. Anfield Capital Management LLC acquired a new stake in shares of Merit Medical Systems in the second quarter valued at approximately $86,000. Farther Finance Advisors LLC raised its holdings in shares of Merit Medical Systems by 32.7% during the third quarter. Farther Finance Advisors LLC now owns 1,056 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 260 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Merit Medical Systems during the second quarter worth approximately $112,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 29,646 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the sale, the chief financial officer now owns 16,361 shares in the company, valued at $1,603,705.22. This represents a 64.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director F. Ann Millner sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.55, for a total value of $1,269,375.00. Following the sale, the director now directly owns 32,391 shares in the company, valued at approximately $3,289,306.05. This represents a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.